Liquid Biopsy Diagnostics: Our Research is Supported by the State of North Rhine-Westphalia. "Fragmentomics by LIQOMICS"
In May, we kicked off our latest research project, “Fragmentomics by LIQOMICS”, supported with approx. €370,000 in funding from the state of North Rhine-Westphalia.
With this project, we aim to push the boundaries of liquid biopsy diagnostics. By analyzing fragmentation patterns of circulating tumor DNA (ctDNA) and applying AI-driven models, we’re working to significantly improve the sensitivity of minimal residual disease (MRD) detection, especially in lymphomas. The technology also holds great potential for application in other cancer types.
See the press release on the official website of ZukunftBIO.NRW.
